Guizhou Tian'an Pharmaceutical Co. Ltd.

Primary objective: After a single oral dose of dapagliflozin tablets (Dapagliflozin Tablets, test preparation T, produced by Shuanghe Tianan Pharmaceutical (Guizhou) Co., Ltd., specification: 10 mg/tablet) and dapagliflozin tablets (Dapagliflozin Tablets, reference preparation R, owned by AstraZeneca AB and produced by AstraZeneca Pharmaceuticals LP, trade name: Andatang®/FORXIGA®, specification: 10 mg/tablet) was administered to healthy study participants under fasting/postprandial conditions, this pilot study mainly investigated the pharmacokinetic parameters and intra-individual coefficient of variation of the test preparation and the reference preparation in healthy study participants under fasting and postprandial conditions, and verified the rationality of the blood drug concentration analysis method, blood collection time, washout period time interval and other settings. Secondary objective: To observe the safety of the test preparation dapagliflozin tablets and the reference preparation dapagliflozin tablets (Andatang®/FORXIGA®) in healthy study participants.

Primary objective: To compare the differences in absorption degree and absorption rate between pioglitazone hydrochloride dispersible tablets (specification: 30 mg) provided by Guizhou Tianan Pharmaceutical Co., Ltd. and pioglitazone hydrochloride tablets (trade name: ACTOS®, specification: 30 mg) certified by Takeda Teba Pharmaceutical Co., Ltd. in healthy Chinese population under fasting and postprandial administration conditions using a single-center, randomized, open, two-dose, two-period crossover, single-dose, fasting and postprandial administration design. Secondary objective: To evaluate the safety of pioglitazone hydrochloride dispersible tablets (specification: 30 mg) provided by Guizhou Tianan Pharmaceutical Co., Ltd. and pioglitazone hydrochloride tablets (trade name: ACTOS®, specification: 30 mg) certified by Takeda Teba Pharmaceutical Co., Ltd. under fasting and postprandial conditions.

A single-center, randomized, open, two-period, self-crossover, single-dose design was used to compare the differences in absorption extent and rate between calcium dobesilate capsules (specification: 0.5 g) produced by Guizhou Tianan Pharmaceutical Co., Ltd. and calcium dobesilate capsules (trade name: Doxium®/Doxium®, specification: 0.5 g) produced by Ebewe Pharma Ges.m.b.H.Nfg.KG in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of calcium dobesilate capsules produced by Guizhou Tianan Pharmaceutical Co., Ltd.